

1 Multiplex PCR Assay to Detect High Risk Lineages of *Salmonella* Typhi and Paratyphi A

2

3 Fahad A Khokhar¹, Derek DJ Pickard¹, Zoe A Dyson^{1,2,3,4}, Junaid Iqbal⁵, Agila K Pragasam⁶,

4 Jobin Jacob John⁶, Balaji Veeraraghavan⁶, Farah N Qamar⁵, Gordon Dougan^{1,7}, Hilary

5 MacQueen⁸, Sushila H Rigas⁸, Mark A Holmes⁹, Ankur Mutreja^{1,6*}

6

7 1. Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department
8 of Medicine, University of Cambridge, Cambridge, CB2 0AW, UK

9 2. London School of Hygiene & Tropical Medicine, London, WC1E 7HT, UK

10 3. Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne,
11 Victoria, 3004, Australia

12 4. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1RQ,
13 UK

14 5. Department of Paediatrics and Child Health, Aga Khan University, Karachi, 74800, Pakistan

15 6. Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India

16 7. The Wellcome Trust, London, NW1 2BE, UK

17 8. School of Life, Health & Chemical Sciences, The Open University, Milton Keynes, MK7
18 6AA, UK

19 9. Department of Veterinary Medicine, University of Cambridge, Cambridge, CB3 0ES, UK

20

21 *Correspondance: Dr. Ankur Mutreja, am872@cam.ac.uk

22

23 **Abstract:** Enteric fever infections remain a significant public health issue, with up to 20
24 million infections per year. Increasing rates of antibiotic resistant strains have rendered many
25 first-line antibiotics potentially ineffective. Genotype 4.3.1 (H58) is the main circulating
26 lineage of *S. Typhi* in many South Asian countries and is associated with high levels of
27 antibiotic resistance. The emergence and spread of extensively drug resistant (XDR) typhoid
28 strains has increased the need for a rapid molecular test to identify and track these high-risk
29 lineages for surveillance and vaccine prioritisation. Current methods require samples to be
30 cultured for several days, followed by DNA extraction and sequencing to determine the
31 specific lineage. We designed and evaluated the performance of a new multiplex PCR assay,
32 targeting *S. Paratyphi* A as well as the H58 and XDR lineages of *S. Typhi* on a collection of
33 bacterial strains. Our assay was 100% specific for the identification of lineage specific *S.*

34 Typhi and *S. Paratyphi A*, when tested with a mix of non-Typhi *Salmonella* and non-
35 *Salmonella* strains. With additional testing on clinical and environmental samples, this assay
36 will allow rapid lineage level detection of typhoid of clinical significance, at a significantly
37 lower cost to whole-genome sequencing. To our knowledge, this is the first report of a SNP-
38 based multiplex PCR assay for the detection of lineage specific serovars of *Salmonella*
39 Typhi.

40

41 **Keywords:** Salmonella; typhoid fever; Typhi; H58; XDR; Diagnostics; PCR

42

43 **Data Statement:** All supporting data, code and protocols have been provided within the
44 article or through supplementary data files.

45

46 INTRODUCTION

47

48 Enteric fever is caused by the bacteria *Salmonella enterica* serovars Typhi and Paratyphi A,
49 B and C. It remains a significant health issue, which is estimated to cause up to 20 million
50 infections and 161,000 deaths per year, predominantly in low and middle-income countries in
51 Southeast Asia and Africa. *S. Typhi* and *S. Paratyphi A* are human restricted pathogens and
52 are transmitted by the faecal-oral route often via contaminated water (1). Vaccination, access
53 to clean water, and improved sanitation are effective means to prevent transmission of
54 typhoid.

55

56 Cases of typhoid fever can be treated with former first-line antibiotics such as
57 chloramphenicol, ampicillin or co-trimoxazole. However, the emergence of multi-drug
58 resistant (MDR) *S. Typhi* in the mid-1970s and the recent emergence of strains with
59 increased anti-microbial resistance (AMR) profiles to more antibiotics (2), has rendered these
60 treatment options potentially ineffective in the near future. Many MDR *S. Typhi* strains
61 possess self-transmissible incompatibility type (IncHI1) plasmids carrying a suite of
62 antimicrobial resistance genes. Haplotype 58 (H58) or genotype 4.3.1 is the dominant *S.*
63 *Typhi* lineage in many parts of Asia and Eastern Africa today and is associated with high
64 levels of multidrug resistance and reduced susceptibility to fluoroquinolones (2).

65

66 Extensively drug-resistant (XDR) *S. Typhi*, first reported in Pakistan in 2016 (3), was found
67 to be an MDR H58 strain that had acquired an IncY plasmid from an *E. coli* isolate
68 harbouring both *bla*CTX-M-15 and *qnrS* resistance genes conferring resistance to ceftriaxone
69 and third generation cephalosporins. This leaves azithromycin as the only viable oral
70 treatment option for XDR *S. Typhi*. However, recent reports of azithromycin-resistant *S.*

71 Typhi and *S. Paratyphi A* in Bangladesh (4) and Pakistan (5) have raised concerns about the
72 potential of this mutation to evolve in XDR strains in the future, further limiting treatment
73 options.

74

75 Current laboratory diagnosis of typhoid fever requires clinical samples to be sent to a
76 centralised laboratory to be processed by bacterial culture and standard identification,
77 followed by susceptibility, serological and/or advanced molecular tests such as real-time PCR
78 and whole-genome sequencing (WGS). Blood culture remains the diagnostic technique of
79 choice but takes several days for results and only identifies 45-70% of confirmed cases. It is
80 also limited by the low numbers of *Salmonella* bacteria in samples ranging from <1-22
81 organisms/ml of blood (6, 7). Sampling from bone marrow has been shown to have greater
82 sensitivity and specificity but that remains a highly invasive procedure. There have been
83 several studies that utilise PCR assays to identify invasive *Salmonella* serovars (8-14) but
84 rely on blood culture over 2-3 days followed by DNA extraction before PCR testing. More
85 recently, studies have shown that the use of ox bile-containing media for the enrichment of
86 bacteria directly from blood samples (15), or the selective removal of human DNA (16),
87 combined with a PCR assay can reduce the turnaround time for diagnosis and increase the
88 diagnostic sensitivity (17). Most importantly, however, is that none of the current routine
89 diagnostic platforms highlighted here offer a resolution to discriminate between low and
90 high-risk lineages in a single test.

91

92 In our study, we designed a simple, rapid, highly specific multiplex PCR assay for the
93 detection of *S. Typhi*, *S. Paratyphi A*, *S. Typhi* H58 and *S. Typhi* XDR, based on single
94 nucleotide polymorphisms (SNPs) specific for these lineages of clinical significance. Once

95 tested on clinical and environmental samples, this will be used to guide clinical and public
96 health decision making.

97

98 **METHODS**

99

100 **DNA extraction and bacterial strains**

101 Bacterial isolates (Table 1) were cultured onto Luria-Bertani (LB) agar plates from frozen
102 stock vials. A single bacterial colony was picked to subculture into 1 ml of LB broth and
103 incubated overnight at 37°C in a shaking incubator. Genomic DNA was extracted from
104 overnight cultures using the Wizard Genomic DNA Purification Kit (Promega, USA).
105 Genomic DNA extracted from *S. Typhi* XDR strains was supplied by Aga Khan University,
106 Karachi, Pakistan. All DNA strains were diluted in 10 mM Tris buffer and quantified using
107 the Qubit 3 fluorometer with the dsDNA broad-range assay kit (Thermo Fisher Scientific,
108 UK). An additional 76 DNA samples were obtained for screening using our PCR assay, that
109 had been previously identified by Matrix-assisted laser desorption/ionization time-of-flight
110 mass spectrometry (MALDI-TOF MS) as *S. Typhi* or *S. Paratyphi A*.

111

112 **Table 1.** Bacterial DNA strains used in testing. All *Salmonella* strains are serovars of *subspecies*
113 *enterica* unless otherwise stated

Bacterial strain	Isolate details
<i>S. Typhi</i> BRD948	H10/15 Ty2 (Δ <i>aroC aroD htrA</i>)
<i>S. Typhi</i> SGB87	98-0664 (H55)
<i>S. Typhi</i>	Quail strain
<i>S. Typhi</i>	lupe GEN0059 (4.1)
<i>S. Typhi</i>	403 Ty (H59 3.1.2)

<i>S. Paratyphi A</i>	AKU_12601
<i>S. Paratyphi B</i>	SPB7
<i>S. Typhi H58</i>	ERL12148
<i>S. Typhi H58</i>	ERL12960
<i>S. Typhi XDR 1</i>	
<i>S. Typhi XDR 2</i>	
<i>S. Typhi XDR 3</i>	
<i>S. Typhi XDR 4</i>	
<i>S. Typhi XDR 5</i>	
<i>S. Enteritidis</i>	PT4
<i>S. Hadar</i>	SC1
<i>S. Infantis</i>	SC31
<i>S. Cholearasuis</i>	SC-B67
<i>S. enterica subsp. arizonae</i>	CDC 346-86
<i>S. enterica subsp. diarizonae</i>	CDC 01-0005
<i>S. Dublin</i>	TYT3627
<i>S. Newport</i>	E2002001708
<i>S. 1,4, (5),12:i</i>	CVM23701
<i>S. Kentucky</i>	CVM29188
<i>S. Heidelberg</i>	CVM30485
<i>S. Javiana</i>	CVM35943
<i>S. Saint Paul</i>	SARA29
<i>S. Pullorum</i>	S449/87
<i>S. Typhimurium</i>	D23580

<i>S. Typhimurium</i>	4/74
<i>Escherichia coli</i>	BL21
<i>Vibrio cholerae</i>	O1 El Tor

114

115

116 **Primer design**

117 Primers targeting highly conserved genes were designed for the detection of *S. Typhi* and *S.*
118 *Paratyphi A* serovars (Table 2). Primers with additional mutations incorporated based on the
119 mismatch amplification mutation assay (MAMA) PCR principle as previously described (18),
120 were designed to selectively amplify a target sequence in the presence of a SNP of interest
121 for H58 and XDR lineages (19). All primers were designed using Primer-BLAST (20),
122 synthesised by Integrated DNA Technologies (IDT, USA) and were resuspended from their
123 lyophilised form in 10 mM Tris buffer. Appropriate amplicon lengths were selected for each
124 target with a minimum of 50 bp difference, in order to effectively separate and be visualised
125 by gel electrophoresis.

126

127 **Table 2.** Primer sequences used in our multiplex assay with expected amplicon sizes generated for
128 each target.

Target	Primer name	Primer sequence (5'-3')	Amplicon length (bp)
<i>S. Typhi</i>	ST_227F	GGCAGATATACTTTCGCAGGCA	227
	ST_227R	CCCAGAACCAAATTTGCTTACA	
<i>S. Paratyphi A</i>	SPA_305F	AGGGATGAGAATTTTCAGACGT	305
	SPA_305R	ACCCAGCTCTGAGAGATATCT	
<i>S. Typhi XDR</i>	XDR_425F	TGAATGGTTCTGGTCTGGCG	425
	XDR_425R	CTAAACCACGACGGCTCAGT	

S. Typhi H58	H58_509F	GGGCTTGATGGCTTCATTAGT	509
	H58_509R	ACAGGTTGTACGCCTTTCCA	

129

130 **PCR protocol**

131 Each PCR reaction contained 5 ng of DNA, 12.5 µl of 2X PCR Master Mix (Thermo Fischer
132 Scientific, UK), 8 or 10 µM each of the forward and reverse primers (Table 1), and nuclease
133 free water to a final volume of 25 µl. All reactions were performed on a T100 thermal cycler
134 (BioRad Laboratories Inc., USA) under the following cycling conditions; 95°C for 2 mins,
135 followed by 30 cycles of 95°C for 30 sec, 60°C for 45 sec, 68°C for 1 min, and final
136 extension at 68°C for 10 mins. The PCR products were run on 1.2% (w/v) agarose gels
137 containing SYBR® Safe DNA Gel Stain (Invitrogen, USA) and visualised on a ChemiDoc
138 MP imaging system (BioRad Laboratories Inc., USA).

139

140 **RESULTS**

141

142 Our multiplex assay not only distinguished *S. Paratyphi A* from *S. Typhi*, but also identified
143 low and high-risk lineages of *S. Typhi* that are of clinical relevance (Figure 1). Optimal
144 conditions were initially determined for singleplex PCR, before adapting for the multiplex
145 reaction. The *S. Typhi* and *S. Paratyphi A* primers were designed from specific regions in
146 their reference genomes that are highly conserved across all strains, genes STY0307 and
147 SSPA2308 respectively. The *S. Typhi* and *S. Paratyphi A* specific primers yielded 227 bp and
148 305 bp amplicon products, respectively.

149

150 Through screening of our Typhi genome collection, we were able to determine SNPs which
151 are specific to certain lineages, as detailed elsewhere (19, 21). These were chosen for use as

152 relevant diagnostic markers. Our marker for the multidrug resistant lineage 4.3.1 (H58) is
153 based on a C→T synonymous mutation (T349T) in the STY2513 gene at position 2348902 in
154 the *S. Typhi* CT18 reference genome, which encodes for the anaerobic glycerol-3-phosphate
155 dehydrogenase subunit A (glpA) gene. This mutation covers all H58 4.3.1 lineage and sub-
156 lineage isolates, with our primers generating a 509 bp sized amplicon product. The diagnostic
157 marker for the XDR lineage (genotype 4.3.1.1.P1) is based on a G→A (E13E) synonymous
158 mutation in the STY0962 gene encoding anaerobic dimethyl sulfoxide reductase chain A
159 precursor (dmsA), at position 955875 of the CT18 genome. Our XDR primers targeting this
160 SNP generate an amplicon size of 425 bp. Figure 2 shows the results of the multiplex assay
161 visualised by gel electrophoresis. Pairwise alignments to the CT18 reference sequence with
162 our H58 and XDR SNPs are summarised in Figure 3 below.

163

164 Our results showed that our initial primers designed for the H58 and XDR targets with just
165 the one SNP incorporated were not specific for these lineages as they were binding to other *S.*
166 *Typhi* strains (data not shown). Further adaptation was made by incorporating an additional
167 SNP at the 3' end of the primer which induced the specificity for the target sequence and
168 strain and subsequently produced no false positive results (Figure 3). To determine the
169 specificity of the assay, we tested the multiplex primers on a range of non-*Typhi Salmonella*
170 and non-*Salmonella* pathogens, which showed no amplification.

171

172 From the additional DNA samples obtained for testing, 75/76 were originally identified as *S.*
173 *Typhi*, with the remaining isolate identified as *S. Paratyphi A*. Using the same PCR
174 conditions listed above, we tested our assay on these samples, with the single *S. Paratyphi A*
175 sample confirmed by producing only a single 305 bp band as expected. Interestingly, 13/75
176 isolates that had previously been identified as *S. Typhi*, only produced the 305 bp *S.*

177 Paratyphi A band in our assay. To investigate these discrepant results, the isolates were later
178 whole-genome sequenced and confirmed as *S. Paratyphi A*. Of the remaining isolates, our
179 PCR assay identified 54/76 as *S. Typhi* H58, 4/76 as *S. Typhi* non-H58/non-XDR, 1/76 as
180 mixed *S. Typhi* and *S. Paratyphi A*, and 4/76 did not produce any bands (data not shown).
181 None of these additional 76 DNA isolates were identified as *S. Typhi* XDR.

182

183 **DISCUSSION**

184

185 Typhoid fever remains a major public health issue particularly in South and Southeast Asia.
186 Early diagnosis is important for detecting cases in patients but also to discover sources of
187 potential outbreaks. It is widely accepted that improved methods for the diagnosis and
188 monitoring of the emergence and spread of *S. Typhi* would facilitate disease control and
189 treatment. Yet there remain difficulties in obtaining sufficient samples for rapid molecular
190 testing as direct blood samples are limited by the low abundance of *Salmonella* bacteria and
191 other sampling methods remain extremely invasive and not widely available. Standard
192 diagnostic techniques also lack the resolution to discriminate between different serovars of *S.*
193 *Typhi* as well as drug-susceptible from drug-resistance strains. An ideal diagnostic for
194 typhoid fever should be high-resolution, rapid, specific, and sensitive for the target organism.

195

196 The widespread dissemination of the H58 lineage in multiple countries, XDR lineage across
197 Pakistan, and the emergence of azithromycin resistant isolates is of concern. The only method
198 to identify and track the spread of such resistant strains is by whole genome sequencing.
199 Based on our SNP-based diagnostic assay, there is potential to design and incorporate PCR
200 primers as an additional target to monitor the spread of such strains at a significantly lower
201 cost compared to complete genome sequencing.

202

203 Our multiplex PCR assay for the detection of *S. Typhi* and *S. Paratyphi A* enables the
204 identification of the MDR H58 and XDR *S. Typhi* lineages. In many countries, *S. Paratyphi*
205 *A* infections are increasingly common, so it was important that this assay could distinguish its
206 presence in a population (22). Our single and multiplex PCR assays found no false positive
207 reaction with non-Typhi serotypes or non-*Salmonella* pathogens, suggesting that the target
208 genes are specific for our *Salmonella* serovar targets. From the additional DNA samples
209 obtained, our assay was able to correctly identify *S. Paratyphi A* isolates that had previously
210 been classified as *S. Typhi* by MALDI-TOF MS, which were subsequently confirmed as *S.*
211 *Paratyphi A* by whole-genome sequencing. Although our assay was able to positively identify
212 XDR *S. Typhi* from extracted DNA from five samples, we acknowledge there is a lack of
213 additional XDR isolates in our collection. A further limitation is that our experiments were
214 performed using DNA extracted from purified cultures and therefore contained few potential
215 PCR inhibitors. Further optimisation of our PCR assay is planned for working directly on
216 bacterial colonies in addition to sampling from environmental water and sewage samples. As
217 direct assays are developed for clinical use in the future, our PCR assay should directly plug
218 in to obtain the lineage level resolution.

219

220 We envision that our multiplex PCR assay will be widely used in routine laboratory diagnosis
221 from DNA extracted after blood culture incubation, and eventually in combination with
222 previously mentioned enrichment methods. Having a low cost, high-resolution, simple PCR
223 test, as opposed to the current expensive whole-genome sequencing methods, allows our
224 assay to be accessible to low- and middle-income countries where improved diagnostics for
225 typhoid fever are most needed. The lineage level rapid detection of *S. Typhi* will make
226 clinical decision making more efficient and help tackle AMR.

227

228 **Funding information**

229 This study was funded by a Bill & Melinda Gates Foundation grant to M.A.H. and A.M., and the National
230 Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University
231 Hospitals NHS Foundation Trust, AMR theme].

232

233 **Author contributions**

234 Conceptualisation and Funding Acquisition: A.M., M.A.H., G.D.; Investigation, Methodology and
235 Visualisation: F.K. and D.J.J.P. Writing – Original Draft Preparation: F.K., D.J.J.P., M.A.H., A.M.;
236 Writing – Review and Editing: all authors.

237

238 **Conflicts of interest**


239 The authors declare that there are no conflicts of interest.


240 **REFERENCES**

241

- 242 1. Typhoid fever: World Health Organisation; [cited 2020 November]. Available from:
243 <http://www.emro.who.int/health-topics/typhoid-fever/>.
- 244 2. Park SE, Pham DT, Boinett C, Wong VK, Pak GD, Panzner U, et al. The
245 phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa.
246 Nature Communications. 2018;9(1).
- 247 3. Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of
248 an Extensively Drug-Resistant Salmonella enterica Serovar Typhi Clone Harboring a
249 Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation
250 Cephalosporins. mBio. 2018;9(1):e00105-18.
- 251 4. Hooda Y, Sajib MSI, Rahman H, Luby SP, Bondy-Denomy J, Santosham M, et al.
252 Molecular mechanism of azithromycin resistance among typhoidal Salmonella strains in
253 Bangladesh identified through passive pediatric surveillance. PLOS Neglected Tropical
254 Diseases. 2019;13(11):e0007868.
- 255 5. Iqbal J, Dehraj IF, Carey ME, Dyson ZA, Garrett D, Seidman JC, et al. A Race
256 against Time: Reduced Azithromycin Susceptibility in Salmonella enterica Serovar Typhi in
257 Pakistan. mSphere. 2020;5(4).
- 258 6. Parry CM, Wijedoru L, Arjyal A, Baker S. The utility of diagnostic tests for enteric
259 fever in endemic locations. Expert Review of Anti-infective Therapy. 2011;9(6):711-25.
- 260 7. Hosoglu S, Wain J. The laboratory diagnosis of enteric fever. The Journal of Infection
261 in Developing Countries. 2008;2(06).
- 262 8. Nasrummassi M. Quantitative detection of serovar Typhi from blood of suspected
263 typhoid fever patients by real-time PCR. International Journal of Medical Microbiology.
264 2005;295(2):117-20.
- 265 9. Levy H, Diallo S, Tennant SM, Livio S, Sow SO, Tapia M, et al. PCR Method To
266 Identify Salmonella enterica Serovars Typhi, Paratyphi A, and Paratyphi B among
267 Salmonella Isolates from the Blood of Patients with Clinical Enteric Fever. Journal of
268 Clinical Microbiology. 2008;46(5):1861-6.
- 269 10. Song JH, Cho H, Park MY, Na DS, Moon HB, Pai CH. Detection of Salmonella typhi
270 in the blood of patients with typhoid fever by polymerase chain reaction. Journal of Clinical
271 Microbiology. 1993;31(6):1439-43.
- 272 11. Massi MN, Gotoh A, Bishnu A, Kawabata M, Shirakawa T, Gotoh A, et al. Rapid
273 diagnosis of typhoid fever by PCR assay using one pair of primers from flagellin gene of
274 Salmonella typhi. Journal of Infection and Chemotherapy. 2003;9(3):233-7.
- 275 12. Chaudhry R, Laxmi BV, Nisar N, Ray K, Kumar D. Standardisation of polymerase
276 chain reaction for the detection of Salmonella typhi in typhoid fever. Journal of Clinical
277 Pathology. 1997;50(5):437-9.
- 278 13. Nga TVT, Karkey A, Dongol S, Thuy HN, Dunstan S, Holt K, et al. The sensitivity of
279 real-time PCR amplification targeting invasive Salmonella serovars in biological specimens.
280 BMC Infectious Diseases. 2010;10(1):125.
- 281 14. Sajib MSI, Tanmoy AM, Hooda Y, Rahman H, Andrews JR, Garrett DO, et al.
282 Tracking the Emergence of Azithromycin Resistance in Multiple Genotypes of Typhoidal
283 Salmonella. mBio. 2021;12(1).
- 284 15. Zhou L, Pollard AJ. A fast and highly sensitive blood culture PCR method for clinical
285 detection of Salmonella enterica serovar Typhi. Annals of Clinical Microbiology and
286 Antimicrobials. 2010;9(1):14.

- 287 16. Zhou L, Pollard AJ. A novel method of selective removal of human DNA improves
288 PCR sensitivity for detection of Salmonella Typhi in blood samples. *BMC Infectious*
289 *Diseases*. 2012;12(1):164.
- 290 17. Neupane DP, Dulal HP, Song J. Enteric Fever Diagnosis: Current Challenges and
291 Future Directions. *Pathogens*. 2021;10(4):410.
- 292 18. Morita M, Ohnishi M, Arakawa E, Bhuiyan NA, Nusrin S, Alam M, et al.
293 Development and validation of a mismatch amplification mutation PCR assay to monitor the
294 dissemination of an emerging variant of *Vibrio cholerae* O1 biotype El Tor. *Microbiology and*
295 *Immunology*. 2008;52(6):314-7.
- 296 19. Dyson ZA, Holt KE. Five years of GenoTyphi: updates to the global Salmonella
297 Typhi genotyping framework. *J Infect Dis*. 2021.
- 298 20. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST:
299 A tool to design target-specific primers for polymerase chain reaction. *BMC Bioinformatics*.
300 2012;13(1):134.
- 301 21. Wong VK, Baker S, Connor TR, Pickard D, Page AJ, Dave J, et al. An extended
302 genotyping framework for *Salmonella enterica* serovar Typhi, the cause of human typhoid.
303 *Nat Commun*. 2016;7:12827.
- 304 22. Bhetwal A, Maharjan A, Khanal PR, Parajuli NP. Enteric Fever Caused by *Salmonella*
305 *enterica* Serovars with Reduced Susceptibility of Fluoroquinolones at a Community Based
306 Teaching Hospital of Nepal. *International Journal of Microbiology*. 2017;2017:1-6.
307





18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 M



